PRTA
NASDAQProthena Corporation plc
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$8.36-0.09 (-1.07%)
01:45 PM07:45 PM
News · 26 weeks49+250%
2026-04-192026-10-11
Mix2890d
- Insider21(75%)
- Other3(11%)
- SEC Filings3(11%)
- Earnings1(4%)
Latest news
25 items- INSIDERSEC Form 4 filed by Prothena Corporation plc4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERSEC Form 4 filed by Prothena Corporation plc4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERSEC Form 4 filed by Prothena Corporation plc4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- SECProthena Corporation plc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
- INSIDERLarge owner Scully William P bought $1,405,674 worth of Ordinary Shares (162,000 units at $8.68) (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERLarge owner Scully William P bought $889,872 worth of Ordinary Shares (103,500 units at $8.60) (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERLarge owner Scully William P bought $843,460 worth of Ordinary Shares (100,000 units at $8.43), increasing direct ownership by 12% to 927,000 units (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- PRProthena to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceProthena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, September 16, 2026 at 8:30 a.m. ET in New York, NY. A live webcast of the fireside chat can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, a replay of the webcast will be available on the Company's website for 90 days following the presentation date. About P
- INSIDERLarge owner Scully William P bought $255,739 worth of Ordinary Shares (27,000 units at $9.47), increasing direct ownership by 3% to 827,000 units (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERLarge owner Scully William P bought $439,430 worth of Ordinary Shares (50,000 units at $8.79), increasing direct ownership by 7% to 800,000 units (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERSEC Form 3 filed by new insider Fennell Todd W.3 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERLarge owner Scully William P received a gift of 336,000 units of Ordinary Shares and gifted 627,553 units of Ordinary Shares, decreasing direct ownership by 28% to 750,000 units (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERLarge owner Scully William P received a gift of 251,553 units of Ordinary Shares, increasing direct ownership by 32% to 1,041,553 units (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERSEC Form 3 filed by new insider Fennell Todd W.3 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERLarge owner Scully William P bought $323,220 worth of Ordinary Shares (37,500 units at $8.62), increasing direct ownership by 4% to 790,000 units (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- SECSEC Form 10-Q filed by Prothena Corporation plc10-Q - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
- SECProthena Corporation plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
- PRProthena Reports Second Quarter 2026 Financial Results and Business HighlightsNet cash used in operating and investing activities was $25.7 million in the second quarter and net cash provided by operating and investing activities was $3.2 million for the first six months of 2026; quarter-end cash and restricted cash position was $289.1 million Guidance updated to include shares repurchased through July 30, 2026 and now expects to end the year with approximately $259 million (midpoint) in cash, cash equivalents and restricted cash Results from partner Roche evaluating prasinezumab in patients with early Parkinson’s disease from the Phase 2b PADOVA clinical trial published in The Lancet Multiple research collaborations with industry partners ongoing to explor
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Prothena Corporation plcSCHEDULE 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)
- INSIDERChief Scientific Officer Zago Wagner M. converted options into 51,000 units of Ordinary Shares and returned $436,560 worth of Ordinary Shares to the company (51,000 units at $8.56) (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERChief Accounting Officer Walker Karin L converted options into 15,000 units of Ordinary Shares and returned $128,400 worth of Ordinary Shares to the company (15,000 units at $8.56) (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERChief Development Officer Swanson Chad J. converted options into 51,000 units of Ordinary Shares, returned $349,248 worth of Ordinary Shares to the company (40,800 units at $8.56) and covered exercise/tax liability with 3,467 units of Ordinary Shares, increasing direct ownership by 20% to 40,733 units (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERChief Operating Officer Smith Brandon S. converted options into 78,000 units of Ordinary Shares and returned $667,680 worth of Ordinary Shares to the company (78,000 units at $8.56) (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERChief Strategy Officer and CFO Nguyen Tran converted options into 57,000 units of Ordinary Shares and returned $487,920 worth of Ordinary Shares to the company (57,000 units at $8.56) (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERPresident and CEO Kinney Gene G. converted options into 84,000 units of Ordinary Shares and returned $719,040 worth of Ordinary Shares to the company (84,000 units at $8.56) (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
PRTA FAQ
6 questionsWhat does Prothena Corporation plc do?
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other...Where does PRTA stock trade?
Prothena Corporation plc (PRTA) is listed on NASDAQ.What sector and industry is PRTA in?
Prothena Corporation plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about PRTA?
Prothena Corporation plc has had 8 recent analyst actions on file. The most recent action was from BofA Securities: Underperform with a $400.00 price target on 2025-05-28.What companies are similar to PRTA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PRTA side-by-side with any of them on Quantisnow.How can I track PRTA on Quantisnow?
Quantisnow aggregates Prothena Corporation plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PRTA to receive live email and push alerts on every new disclosure.